Disclosures: Speaker: Warner Chicott, Pfizer; Consultant: Palatin Technologies, Pfizer, Boerhringer Ingelheim.
Breast Cancer and Sexuality: Multi-modal Treatment Options (CME)
Article first published online: 7 DEC 2011
© 2011 International Society for Sexual Medicine
The Journal of Sexual Medicine
Volume 9, Issue 1, pages 5–13, January 2012
How to Cite
Krychman, M. L. and Katz, A. (2012), Breast Cancer and Sexuality: Multi-modal Treatment Options (CME). Journal of Sexual Medicine, 9: 5–13. doi: 10.1111/j.1743-6109.2011.02566.x
- Issue published online: 4 JAN 2012
- Article first published online: 7 DEC 2011
- Breast Cancer;
- Female Sexual Dysfunction;
The sexual consequences of breast cancer and its treatments are well known and previously reviewed. Alterations in body image, with or without breast reconstruction, changes in sexual self-esteem and self-efficacy, vulvovaginal atrophy as a result of chemotherapy and/or adjuvant hormone therapy, and loss of libido secondary to dyspareunia and body image issues are common in survivors of breast cancer. Medications that are prescribed for long-term use including those in the class of aromatase inhibitors can have far-reaching implications on quality of life by contributing to vulvar and vaginal atrophic changes. While this is an important issue, there are few widely accepted treatments that have been evaluated for efficacy and safety for these sexual challenges in the breast cancer population. However, progress is being made in finding new and innovative solutions for many of the sexual problems faced by breast cancer survivors and their partners. Many institutions are now compelled to address survivorship concerns and addressing sexuality and intimacy are paramount issues in survivorship care. In this article, we present the evidence for the multimodal approach to the management of sexuality concerns in the breast cancer survivor. Pharmacologic, nonpharmacologic, and psychosocial interventions will be reviewed. Krychman ML and Katz A. Breast cancer and sexuality: Multi-modal treatment options. J Sex Med **;**:**–**.